Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial

Helen Dakin, S Wordsworth , Chris Rogers, G abangma, J Raferty , Simon P Harding, Andrew J Lotery, S M Downes, Usha Chakravarthy, Barnaby Reeves

Research output: Contribution to journal › Article (Academic Journal) › peer-review

59 Citations (Scopus)

Search results